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Abstract: The proteasome is the central component of the main cellular protein degradation pathway.
During the past four decades, the critical function of the proteasome in numerous physiological
processes has been revealed, and proteasome activity has been linked to various human diseases.
The proteasome prevents the accumulation of misfolded proteins, controls the cell cycle, and
regulates the immune response, to name a few important roles for this macromolecular “machine.”
As a therapeutic target, proteasome inhibitors have been approved for the treatment of multiple
myeloma and mantle cell lymphoma. However, inability to sufficiently inhibit proteasome activity at
tolerated doses has hampered efforts to expand the scope of proteasome inhibitor-based therapies.
With emerging new modalities in myeloma, it might seem challenging to develop additional
proteasome-based therapies. However, the constant development of new applications for proteasome
inhibitors and deeper insights into the intricacies of protein homeostasis suggest that proteasome
inhibitors might have novel therapeutic applications. Herein, we summarize the latest advances
in proteasome inhibitor development and discuss the future of proteasome inhibitors and other
proteasome-based therapies in combating human diseases.
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1. Introduction
Cells have evolved intricate regulatory mechanisms to adjust their proteomes in response to
intracellular and environmental conditions, allowing for healthy growth and survival [1]. Aberrancies
in protein synthesis, folding, trafficking and degradation can lead to many human illnesses and
diseases, including neurodegenerative disorders, cancers, and autoimmune diseases [2–4]. The link
between protein homeostasis, or proteostasis, and human health have motivated expansive efforts
over the past three decades to discover and develop modulators of the major mammalian protein
degradation pathway: the ubiquitin-proteasome system (UPS) [5,6]. The UPS is involved in a range
of essential cellular processes, including cell-cycle progression, antigen presentation, inflammation,
apoptosis, DNA repair, signal transduction, and protein quality control [7,8]. For example, the UPS is
central to the unfolded protein response (UPR), which is activated when unfolded or misassembled
proteins accumulate in the endoplasmic reticulum (ER). The UPR leads to apoptosis if ER stress is not
mitigated [9,10]. The UPS is also critical for regulating the transcription factor NF-κB, thereby affecting
the inflammatory response in addition to apoptosis and oncogenesis [11,12]. Neurons rely heavily on
the UPS for maintaining proteostasis because of their long lifespans and specialized architectures, and
deficiencies in the UPS are hallmarks of neurodegeneration [13–15].
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While the fundamental mechanistic and structural details of the proteasome are still active areas
of investigation [16], the use of proteasome inhibitors in clinic has proven to be successful in treating
cancer, specifically multiple myeloma (MM) and mantle cell lymphoma (MCL), with the number
and types of disease indications growing [17–20]. However, there are considerable challenges with
using proteasome inhibitors because of the critical role that the proteasome plays in fundamental
cellular processes. Additionally, while proteasome inhibitors have been successfully employed to treat
cancer, where inhibiting uncontrolled cell growth is important, there are other circumstances in which
activating the proteasome could be advantageous, including in the treatment of neurodegeneration.
Proteasome activation has also been found to delay retinal degeneration in mice [21]. There is a fine
line between having too much and too little proteasome activity; in some circumstances, one might
want more proteasome activity, while in others, it is better to have less. There also must be a balance
between preserving enough proteasome activity for survival of most cells in the body and eliminating
unwanted activity in specific cells types or organs. With the number of clinical trials involving
proteasome inhibitors alone or in combination with other therapies growing, and diseases treated
with proteasome inhibitors expanding, it is an exciting time to think about how to improve current
proteasome inhibitors and novel strategies for developing new ones. In addition to highlighting the
current state of proteasome inhibitors in laboratory and clinic, this review will offer perspectives on how
to improve the efficacy of current proteasome inhibitors (alone or as combination therapies), directions
for developing new UPS inhibitors (including for targets other than the proteasome itself), and
fundamental research directions that will enhance proteasome inhibitor development and validation.
1.1. Proteasome: Structure and Function
1.1.1. 26S Proteasome
The presence of a soluble ATP-dependent “proteolytic machine” was discovered in the 1970′s [22],
and the identification and characterization of the proteasome and the role of ubiquitin in protein
degradation emerged over the following 20 years [5,8,23,24]. The proteasome is a 2.4 megadalton
multi-subunit enzyme complex of the conserved AAA+ (ATPase associated with various cellular
activities) family [25]. The 26S proteasome degrades the majority (at least 80%) of proteins in the
cytoplasm and nucleus of mammalian cells [26]. Proteasome substrates include misfolded or damaged
proteins in addition to regulatory proteins that need to be degraded for proper cellular function.
The central component of the 26S proteasome is the 28-subunit “core particle” (CP) comprising four
stacked heptameric rings that form a donut-shape (referred to as the 20S proteasome). The middle of the
donut creates an axial pore through which unfolded polypeptides are translocated (Figure 1A). The two
outermost rings, formed by seven α-subunits, mediate interactions between the central pore and the
cellular environment. The innermost rings are formed by seven β-subunits, and three of these subunits
contain the proteasome’s enzymatic active sites. The N-terminal threonine of each enzymatic subunit
serves as both the nucleophile and primary proton acceptor in the peptide bond cleavage reaction.
Each active site has similar cleavage specificity to a known protease: β1 has caspase-like specificity, β2
has trypsin-like specificity, and β5 has chymotrypsin-like specificity. Despite the proclivity of each
active site to cleave after certain amino acid types, the close proximity of the six sites facing the narrow
axial pore allows for the processive degradation of a broad range of primary amino acid sequences
into small peptides (~10 amino acids). These peptides can be further processed and used for antigen
generation, or the amino acids can be recycled for new protein synthesis [27].
What prevents the proteasome from nonspecifically degrading cellular proteins? First, the active
sites are sequestered within a deep pore, topologically preventing nonspecific proteolysis. The narrow
radius of the pore prevents folded proteins from entering. Second, the CP itself is auto-inhibited
by the N-terminal tails of the α-subunits [28], requiring regulatory factors to open the gates of the
channel [29,30]. This allows for multiple regulatory checkpoints before a substrate is degraded.
The main regulatory component of the 26S proteasome is the 19S regulatory particles (RP), also known
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as PA700, that caps either or both ends of the 20S CP (Figure 1B). The 19S RP is remarkably complex
and comprises 19 stoichiometric subunits and many sub-stoichiometric interacting proteins [8,31]. UPS
substrates must pass through this complex in order to be degraded, as the 19S RP opens the gates of
the central channel of the 20S CP.
Prior to proteasomal degradation, proteins must be properly “tagged” and targeted to the
proteasome. A cascade of enzymes, known as E1, E2, and E3 enzymes, are responsible for this “tagging”
(Figure 1C). These enzymes catalyze isopeptide bond formation between the C-terminus of an 8 kDa
protein called ubiquitin and the lysine side chain of the substrate (“acceptor”) protein. Ubiquitin
chains can be elaborated by attaching additional ubiquitin moieties to any of its seven lysine residues,
or the N-terminal amino group. At least four ubiquitin molecules are required to tag a substrate for
proteasomal degradation [32], although there are some reported exceptions to this rule [19]. The large
diversity of E3 enzymes in mammalian cells confers substrate specificity for ubiquitin conjugation.
Ubiquitin chains are often expanded to form chains of different sizes and with branches at different
lysine residues within the ubiquitin protein. Poly-ubiquitin chains, especially with K48 linkages,
selectively mark proteins for degradation by the 26S proteasome [8]. Therefore, this complex pathway
diversifies the range of substrates for the proteasome and enhances the regulation of proteins destined
for degradation [33].
The 19S RP is divided into two biochemically separable sub-complexes: the base and the lid [34].
The distal lid contains at least nine proteins that are responsible for ubiquitin binding and removal.
One core component of the lid is a Jab1/MPN domain-associated metalloisopeptidase (JAMM)
domain-containing protein Rpn11 (POH1/PSMD14) that couples deubiquitination with degradation
(Figure 1B) [35,36]. The development of Rpn11 inhibitors might have the ability to expand effective
UPS inhibitors in the clinic, as discussed below [37–40]. The base of the 19S RP includes a ring-shaped
heterohexamer of AAA+ ATPases that engage and unfold substrate polypeptides to allow for their
translocation into the proteolytic pore of the 20S CP [8,16,31]. The ATPases couple ATP hydrolysis
with the mechanical opening of the gates in the α-subunits of the 20S core.
1.1.2. Alternative Proteasome Complexes
In addition to the 26S proteasome, there are several other 20S complexes that catalyze ubiquitin-
and ATP-independent degradation and serve a variety of roles in cells. These complexes include
proteasome “activators” that open the gates of the central pore of the 20S CP, as the CP itself has
very limited basal activity because of its auto-inhibition. Notably, the alternative 20S caps do not
have polypeptide unfoldase activities. One such complex contains the 11S activator (PA28) in place
of the 19S RP (Figure 1D). The 11S activator is mostly found in higher eukaryotes and is induced by
interferon gamma, although there is basal expression in all tissues [19,41]. There are three different
PA28 subunits (α, β and γ) that can form two kinds of heptameric barrel-like structures (either with
PA28αβ or PA28γ). C-terminal motifs in PA28 subunits bind the α-subunits of the 20S CP and contain
an internal activation loop that is involved in pore opening [42–44]. PA28αβ plays a role in antigen
processing and MHC Class I antigen presentation [45–47]. Additionally, PA28γ has been shown to
promote the degradation of cell cycle regulatory proteins such as p21 and SRC-3 [48,49]. Blm10/PA200
is another ubiquitin- and ATP-independent proteasome activator that is mostly found in the nucleus
and has been implicated in such processes as DNA repair, mitochondrial function, and spermatogenesis
(Figure 1D) [50–53]. Unlike the 11S activator, Blm10/PA200 is a monomeric ~250 kDa protein, conserved
from yeast to higher eukaryotes, that forms a dome around the entrance to the 20S pore and makes
extensive contacts with the α-subunits of the 20S CP. Blm10/PA200 has been found to stimulate the
hydrolysis of small peptides and the unstructured tau protein in vitro [54]. Cumulatively, label-free
quantitative proteomic analysis indicates that less than 10% of total cellular proteasomes are bound to
ubiquitin-independent activators [55]; however, recruitment of PA28γ and PA200 to proteasomes is an
unexpected consequence of catalytic inhibition, suggesting that their roles in cell biology might have
clinical significance, such as in resistance to proteasome inhibition [56]. Additionally, the biological
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roles and structural characterization of hybrid proteasome complexes containing one 19S RP and one
alternative cap raise the possibility that alternative proteasome structures, which can be “tuned” to
specific cellular and environmental contexts, might be important therapeutic targets [57–60].
The presence of ATP- and ubiquitin-independent roles for the proteasome highlights the fundamental
question of how substrates are specifically and selectively targeted for degradation. To be degraded,
there must be a proteasome targeting mechanism, and ubiquitin solves that problem for UPS substrates.
What about substrates that are degraded in a ubiquitin-independent manner? This is largely an
unanswered question, but it is clear that proteins degraded in a ubiquitin-independent manner must be
intrinsically disordered or contain disordered regions in order to fit into the proteolytic core [13]. It is
estimated that up to 41% of eukaryotic proteins have intrinsically disordered regions, suggesting, at
least in principle, that a significant portion of the proteome can be degraded in a ubiquitin-independent
manner [61]. Well-characterized proteins that are degraded in a ubiquitin-independent manner include
the yeast transcription factor Rpn4, thymidylate synthase, and ornithine decarboxylase [62]. Interestingly,
in the case of ornithine decarboxylase, proteasomal degradation requires ATP and is accelerated by
antizyme I; additionally, ubiquitinated substrates or free polyubiquitin chains compete for its proteasomal
recognition [63,64]. This suggests that the same machinery responsible for ubiquitin-dependent
degradation can also degrade proteins in a ubiquitin-independent manner. Discovering new substrates of
ubiquitin-independent proteasome degradation pathways, and mechanistic details of these pathways,
will be informative for developing inhibitors that block degradation of particular proteins important in
human health and disease. Conversely, activating proteasomal degradation of intrinsically disordered
proteins could be useful for treating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s
disease, and amyotrophic lateral sclerosis [13].
1.1.3. Immunoproteasome
During oxidative stress or in response to proinflammatory cytokines (e.g., interferon-gamma),
cells produce specialized proteasome assemblies called immunoproteasomes [65]. Antigen-presenting
cells have greater basal expression levels of immunoproteasome subunits. Immunoproteasomes
are large proteasome complexes that are nearly identical to the constitutive proteasome except
for different catalytic β-subunits (β1i, β2i, and β5i) that share high sequence homology with the
associated constitutive proteasome β-subunits [65,66] (Figure 1). Interestingly, the immunoproteasome
has a different substrate specificity than the constitutive proteasome and favors production of
peptides that terminate in basic or hydrophobic amino acids [67–71]. Therefore, immunoproteasomes
enhance ligand generation for MHC Class I molecules, allowing for surveillance by CD8+ T
lymphocytes. Immunoproteasome formation following cytokine induction is rapid, cooperative,
and can be transient [72–74]. Originally thought to be strictly involved in antigen presentation,
immunoproteasomes have also been implicated in other cellular processes, including T cell polarization
and cytokine production by macrophages [66]. Immunoproteasomes generate different peptides
than constitutive proteasomes because they contain slightly different substrate binding pockets [75].
There is considerable effort to generate immunoproteasome-specific inhibitors, as immunoproteasome
complexes appear to be present at low levels normally but higher levels in certain cancers, inflammatory
diseases, and autoimmune diseases. Therefore, immunoproteasome inhibitors can be more selective
and have fewer toxic side effects than constitutive proteasome inhibitors [76,77]. KZR-616, the only
immunoproteasome inhibitor that has advanced to clinical trials, is described below. Based on the
reversible epoxyketone β5i inhibitor ONX0914, the compound shows minimal cross-reactivity with
the constitutive β5 subunit [17]. Advances in understanding the structural differences between the
constitutive proteasome and the immunoproteasome will lead to the development of better, more
specific and potent immunoproteasome inhibitors [66,75,78,79]. In addition to the immunoproteasome,
it should be noted that there is a thymus-specific proteasome (thymoproteasome) that is involved in
thymic positive selection and the development of CD8+ T lymphocytes [72,80]. The thymoproteasome
incorporates a different β5 subunit, denoted β5t, and thymoproteasome-expressing cells display a
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unique set of antigenic peptides [72,80,81]. Finally, the testes-specific spermatoproteasome contains
unique 20S proteasomal subunits in addition to some immunoproteasome subunits [82]. The PA200
activator is also abundant in testes and plays a role in spermatogenesis [83,84].
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Figure 1. Proteasome and ubiquitin-mediated degradation [85]. (A) Schematic of substrate protein
degradation by passage through the central pore of the four stacked heptameric rings that comprise the
20S proteasome (left). The X-ray crystal structure of the yeast 20S proteasome (PDB 1RYP) shows the
two capping α-heptameric rings (red/violet) and he middle two β-heptamers (grey; middle). The central
p re throu h w ich substrates are threaded is indicated in the top view (right). (B) The 26S proteasome
is the central component of the UPS. A cartoon depiction of the components of the 26S proteasome
highlights the lid and base of the 19S RP in addition to the DUB Rpn11 and the catalytic β-rings
(left). The cryo-EM structure of the human 26S proteasome (PDB 6MSB) shows the structure of the
26S proteasome in a state competent for ubiquitinated substrate engagement. (C) Schematic of the
ubiquitin-proteasome system (ubiquitin PDB 1UBQ). (D) Schematic of alternative 20S proteasome
complexes with a heptameric PA28 cap or a monomeric PA200 cap.
2. Proteasome Inhibitors
Scientists have been using proteasome inhibitors for many years to interrogate the biological
function of the proteasome and its involvement in various cellular processes. The essential role of
the proteasome in cell biology makes proteasome inhibition challenging to manage: one wants to
achieve enough inhibition to kill diseased cells that rely heavily on the proteasome but not healthy
cells. Complete proteasome inhibition is toxic. This was the early rationale for developing proteasome
inhibitors to treat neoplastic cells that proliferate rapidly and have aberrant cell cycle checkpoint
regulation [86]. Proteasome inhibitors are especially effective at treating hematological cancers because
of the high dependence of these cancer cells on proteostasis mechanisms (i.e., they have a high secretory
load) [17,87–89]. These cancer cells rely heavily on several mechanisms collectively called ER-associated
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degradation (ERAD), which dislocate aberrantly folded secretory and membrane proteins from the ER
to the cytosol, where they are degraded by the proteasome [90]. We discuss the range of proteasome
inhibitors used in the clinic for treating hematological cancers, and those under investigation in the lab
for treating other forms of cancer and diseases.
2.1. Structural Characteristics of Proteasome Inhibitors
The proteasome inhibitors discussed in this review are largely covalent electrophilic inhibitors
that react with the active-site threonine residues of the proteasome. The first proteasome inhibitors
were analogs of serine protease inhibitors: hydrophobic peptide aldehydes that mimicked substrates
of the β5 active site. Peptide aldehydes react with the nucleophilic hydroxyl group of threonine to
form reversible hemiacetal adducts. One of the early aldehyde inhibitors, MG132, is a tool compound
that is still used by many researchers today. However, MG132 has off-target effects in cells, including
the inhibition of cathepsin B and calpains [7]. As a consequence of its structure, it is also quickly
oxidized. In the years following the discovery of MG132, there were major advances in the development,
optimization, and applications of new proteasome inhibitor structural scaffolds. Other structural classes,
such as peptide boronates (e.g., bortezomib and ixazomib) and peptide epoxyketones (e.g., carfilzomib,
oprozomib, and immunoproteasome-specific inhibitors ONX0914 and KZR-616), have had great
success in the clinic, in part because the active-site adducts that they form are stabilized by specific
interactions with the threonine amino group. For example, peptide boronates have an additional
stabilizing hydrogen bonding interaction, and epoxyketones form stable morpholine adducts [18].
These additional interactions greatly reduce the off-rates of these inhibitors, making some of them
essentially irreversible under physiological-treatment conditions. While most clinical proteasome
inhibitors are covalent peptidic molecules, we also describe a nonpeptidic inhibitor, marizomib, which
contains a reactive β-lactone that forms a tetrahydrofuran ring with the active-site threonine [18].
While more specific than peptide aldehydes, β-lactone inhibitors are less specific than epoxyketones.
Nonpeptidic inhibitors were also developed for the immunoproteasome with the aim of improving
metabolic stability and bioavailability, which is a general liability of peptidic backbones [91–93].
The lead compound from a virtual-screening effort showed excellent selectivity for β5i compared to
the constitutive®5 subunit [91]. However, the cell-based activity of this compound is much weaker
than that of ONX0914 [91]. More efforts are needed to improve the compound’s potency. Efforts to
screen for novel nonpeptidic inhibitors of the constitutive proteasome and immunoproteasome could
result in molecules with improved pharmacokinetics and broader therapeutic potential. However,
with significant interest in improving peptidic therapeutics [94], it is unclear which class of molecule is
ultimately most efficacious in the proteasome inhibitor space.
The enzymatic mechanism of the 20S proteasome has prompted certain electrophilic structural
classes of inhibitors to stand out, and the peptidic nature of many 20S inhibitors resembles natural
proteasome substrates. In addition to inhibiting the 20S proteasome, there are multiple new inhibitors
that target other UPS components, conferring unique phenotypes and toxicity profiles when used in
preclinical studies. These inhibitors also represent more diverse structural classes than 20S inhibitors
because of their mechanisms, opening the door to other therapeutic indications. Although proteasome
inhibitors have seen the most success to date in treating MM and MCL, the list of inhibitors being
tested, either alone or in combination with other drugs, to treat solid tumors and other diseases is long
and growing.
2.2. Proteasome Inhibitors in Clinic
2.2.1. Bortezomib (Velcade)
Bortezomib was the first clinically approved proteasome inhibitor and is now indicated for the
treatment of newly diagnosed multiple myeloma (NDMM) and relapsed MCL (Figure 2). The introduction
of bortezomib into the clinic was a milestone in the treatment of MM, prolonging progression-free
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survival, and improving overall survival in patients with NDMM [95–97]. Bortezomib is a slowly
reversible peptide boronate inhibitor that binds the catalytic site of the 20S proteasome, enabling the
potent inhibition of the chymotrypsin-like activity of theβ5 subunits (IC50, 7 nM; Table 1) [98]. Bortezomib
also inhibits the trypsin-like activity of the β2 subunits and caspase-like activity of the β1 subunits at
high concentrations, but these inhibitory activities are much less potent compared to its inhibition of the
β5 sites [98]. Since its FDA approval in 2003 for refractory disease, bortezomib has become the frontline
therapy for MM patients [99]. At therapeutic doses, bortezomib inhibits approximately 65% of β5 activity
in patient whole blood lysate, which effectively induces apoptosis in myeloma cells without causing
toxicity to nontransformed cells [89,100]. Given the essential role of the proteasome in all cells, it is
critical to understand the mechanism of bortezomib specificity for MM cells. Physiologically, MM cells
have elevated NF-κB activity, which is vital for their survival and proliferation [101,102]. Proteasome
inhibitors block the NF-κB pathway by inhibiting the proteasomal degradation of the NF-κB inhibitor
IκB, therefore enhancing the therapeutic efficacy of conventional treatments such as dexamethasone and
lenalidomide [103]. This partially explains the reason why bortezomib specifically targets transformed
MM. However, it is unlikely to be bortezomib’s critical mechanism of action because other NF-κB pathway
inhibitors, like IκB kinase inhibitors, cannot kill MM cells as effectively as bortezomib [104]. An additional
explanation for the sensitivity of MM cells to bortezomib is the cells’ low tolerance for proteotoxic stress.
Bortezomib inhibits the primary protein-recycling machinery in cells, leading to the accumulation of
misfolded proteins and UPR induction. A sustained UPR signal eventually triggers irreversible cell
death [89]. MM cells produce large quantities of antibodies and rely heavily on the protective UPR. A brief
exposure to the proteasome inhibitor can tip the balance to a terminal UPR, which commits MM cells
to an apoptotic fate [88]. Therefore, MM cells appear to be prone to a cytotoxic bortezomib-induced
terminal UPR.
Table 1. Proteasome inhibitors in the clinic and in clinical trials.
Name Type
IC50 (nM)
β5
Dissoc. T1/2
(min)
Administrationβ5
Chymotrypsin-
Like
β1
Caspase-
Like
β2
Trypsin-
Like
Bortezomib
(PS-341) Boronate 2.4–7 *
,# 24–74 *,# 1200–4200 *,# 110 # Intravenous
Carfilzomib
(PR-171) Epoxyketone 6 * 2400 * 3600 * Irreversible Intravenous
Ixazomib
(MLN9708) Boronate 3.4
# 31 # 3500 # 18 # Oral
Marizomib
(Salinosporamide A) β-lactone 3.5 * 430 * 28 * Irreversible Intravenous
Oprozomib
(ONX0912) Epoxyketone 36
ˆ NA NA Irreversible Oral
* [98]; # [105]; ˆ [106].
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2.2.2. Carfilzomib (Kyprolis)
The success of bortezomib inspired researchers to hunt for a new generation of proteasome
inhibitors to overcome its shortcomings. In 2012, the FDA approved the first second-generation
proteasome inhibitor, carfilzomib (Kyprolis). Carfilzomib is an epoxyketone with a structure based on
the natural product epoxomicin (Figure 2) [115]. It inhibits the chymotryptic activity of the β5 subunit
with high potency and specificity, with an IC50 value of ~6 nM (Table 1) [98]. Unlike bortezomib,
carfilzomib is an irreversible inhibitor that forms a dual covalent bond with active site Thr1 in the β5
subunits [116]. Compared to bortezomib, carfilzomib significantly prolonged the progression-free
survival in patients with refractory and relapsed MM [117,118]. Combination therapy with carfilzomib
and immunomodulatory drugs for NDMM was also evaluated in multiple clinical trials. This treatment
regimen was shown to be efficacious with a favorable safety profile in NDMM [119]. The major adverse
event of bortezomib, peripheral neuropathy, was found to be less severe in patients receiving carfilzomib
treatment [118]. Across several clinical trials, 18.1% of phase 1–3 MM patients treated with carfilzomib
experienced adverse cardiovascular events of all grades [120]. These complications can be managed by
a combination of basic risk assessments, hydration, cardiovascular monitoring, intervention (such as
reducing the carfilzomib dose), and patient education to notice cardiovascular symptoms and regularly
monitor blood pressure [121]. Clinical guidelines were developed in collaboration with cardiologists
to minimize the risk of cardiovascular events in patients treated with carfilzomib [122]. Despite the
improvements of carfilzomib over first-generation proteasome inhibitors, it still has to be administered
intravenously, and has demonstrated limited efficacy in patients with solid tumors [123]. The lack of
efficacy is potentially due to the different physiology in solid tumors, and the pharmacokinetics of the
“omib” drugs [89].
2.2.3. Ixazomib (Ninlaro)
In 2015, a third proteasome inhibitor, ixazomib (Ninlaro), was approved by the FDA to treat
relapsed/refractory MM [124]. It was developed as a second-generation peptide boronic acid-based
proteasome inhibitor and, notably, was the first orally available proteasome inhibitor (Figure 2) [105].
It is administered as a boronic ester prodrug that rapidly hydrolyzes to form the active inhibitor [105].
Although both bortezomib and ixazomib are reversible inhibitors from the same class with similar
potencies, ixazomib has a much faster off-rate for proteasome binding than bortezomib (18 vs. 110 min
t1/2; Table 1) [105,125]. When bortezomib is bound to the proteasome in red blood cells, its slow
dissociation rate limits the drug distribution. Ixazomib was developed to overcome this limitation.
Ixazomib’s fast off-rate allows for it to associate and dissociate with multiple proteasomes, allowing
for its accessibility to more cells and larger tissue distribution [105].
2.3. Proteasome Inhibitors in Clinical Trials
2.3.1. Marizomib
Marizomib is a natural product isolated from the marine actinomycete Salinispora tropica, and the
only nonpeptidic proteasome inhibitor currently in clinical trials (Figure 2) [126,127]. The combination
of marizomib, pomalidomide, and low-dose dexamethasone has demonstrated promising activity
in heavily pretreated, high-risk relapsed/refractory multiple-myeloma patients [126]. Marizomib
is an orally available drug that belongs to the β-lactone chemical family and irreversibly inhibits
the activity of all catalytic β subunits [128,129]. It is one of the most potent inhibitors against the
proteasome’s chymotryptic activity, with an IC50 value of ~3 nM (Table 1) [98,130]. Marizomib was
demonstrated to treat patients with relapsed and/or refractory MM, either alone or in combination
with other drugs, without some of the side effects (e.g., peripheral neuropathy) of other proteasome
inhibitors [126,131]. It is also the smallest proteasome inhibitor identified to date and, likely because
of its more lipophilic structure, the only proteasome inhibitor in clinical trials that can cross the
blood–brain barrier [132]. These unique properties make marizomib an attractive candidate for the
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treatment of central-nervous-system (CNS) malignancies. Marizomib was found to induce caspase
9-dependent cell death in glioblastoma (GBM) cells and mouse models [133]. Currently, it is in clinical
trials for treating newly diagnosed GBM [134].
2.3.2. Oprozomib
Oprozomib is the result of efforts to develop orally available epoxyketone proteasome inhibitors
(Figure 2) [106,135]. It belongs to the same molecular family as carfilzomib and irreversibly inhibits the
β5 subunit (Table 1) [106]. It is in clinical trials for treating newly diagnosed and relapsed/refractory
MM. The trials indicate that oprozomib shows encouraging activity in both relapsed/refractory and
newly diagnosed MM. It could become an important MM therapy if the concerns regarding its
gastrointestinal tolerability are addressed [136–139]. Oprozomib has also been evaluated for treating
solid tumors, but unfortunately no valid treatment efficacy has been observed so far [140]. However,
considering that the patients in the ongoing clinical study were pretreated with other therapies and
have advanced cancers, the efficacy of oprozomib for treating earlier stages of cancer is yet to be
determined [140].
2.3.3. KZR-616
KZR-616 is the only immunoproteasome inhibitor that has advanced to the stage of clinical
trials [141]. It was developed on the basis of ONX0914, an epoxyketone that selectively inhibits the β5i
subunit with an IC50 of ~39 nM (Figure 2 and Table 2) [142]. Unlike constitutive β5 inhibitors, such as
bortezomib and carfilzomib, it reduces the production of proinflammatory cytokines and cell-surface
MHC Class I expression without apoptotic effects [142]. ONX0914 has shown efficacy in animal models
of autoimmune disorders without affecting normal immune function [143,144]. Compared to ONX0914,
KZR-616 has improved solubility and shows better efficacy in mouse models of antibody-induced
arthritis [141]. It is in clinical testing to treat autoimmune diseases [141], expanding the indications
of proteasome inhibitors beyond cancer. Notably, a second immunoproteasome inhibitor, M3258,
targeting β5i was disclosed and will be tested in combination with dexamethasone in an upcoming
phase I clinical trial for treating MM [145].
Table 2. Immunoproteasome inhibitors.
Name Type
IC50 (nM)
Against Immuno- and Constitutive- Proteasome [141]
LMP7
(β5i) β5
LMP2
(β1i) β1
MECL-1
(β2i) β2
ONX0914 Epoxyketone 39 422 287 >12700 902 927
KZR-616 Epoxyketone 39 688 131 >10600 623 604
2.4. Proteasome Inhibitors in Lab
The history of proteasome inhibitor development teaches us two critical lessons: (i) MM is a
starting point but not an end point for proteasome inhibitor-based therapies, and there are more
therapeutic areas worth exploring; and (ii) despite the tremendous patient benefits conferred by
proteasome inhibitors over the last decade, there are opportunities to expand their utility. There is
sustained enthusiasm for identifying other mechanisms to inhibit the proteasome because: (i) inhibition
of the 20S core particle by ‘omibs’ may not be the best route to inhibit the proteasome; (ii) other
mechanisms of proteasome inhibition may provide benefits to patients who are refractory to bortezomib
and carfilzomib; (iii) other mechanisms of proteasome inhibition, when combined with carfilzomib,
may yield synergistic effects that provide even more dramatic progression-free survival; and (iv) the
improved potency and selectivity of carfilzomib and potentially other classes of proteasome inhibitors
may allow for expansion into other hematological malignancies and solid tumors. Therefore, we
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describe alternative strategies to develop non-conventional proteasome inhibitors in the lab with the
potential for use as therapeutics in the future.
2.4.1. Block the Removal of Ubiquitin Chains from Substrates: Rpn11 Inhibitors
Rpn11 is an essential subunit of the 19S RP, which removes the polyubiquitin (polyUb) chains
from substrates prior to degradation (Figure 1B) [35,146]. The active site is located within the JAMM
domain of Rpn11, which contains a catalytic zinc ion coordinated by two histidine residues and an
aspartate [147,148]. Importantly, substrate deubiquitination by Rpn11 is essential for degradation,
to which it is tightly coupled [35,146]. Inactivation of the Rpn11 enzymatic active site by mutations
of the zinc-coordinating histidine residues results in a severe decrease in substrate degradation in
cells [33,149]. An HTS campaign with more than 300,000 compounds was conducted to discover
Rpn11 inhibitors and led to the discovery of a metal-binding pharmacophore with a moderate IC50 of
2.5 µM [40,150]. Further optimization of this hit compound yielded capzimin, a more specific inhibitor
with a biochemical IC50 of ~300 nM against Rpn11 (Table 3 and Figure 3) [40]. Capzimin blocks
proteasome function by inhibiting the deubiquitinase activity of Rpn11, which causes accumulation of
polyubiquitinated proteins, triggers the UPR, and blocks cell proliferation [40]. Capzimin is active
against multiple cancer cell lines, including bortezomib-resistant cells [40]. In addition to capzimin,
natural products such as thiolutin and gliotoxin were also identified as active inhibitors of JAMM
proteases, including Rpn11. These compounds are active in cell culture and inhibit proteasome function
by chelating the zinc ion in the Rpn11 active site [38,39]. However, these compounds are less specific
towards Rpn11 than capzimin. Capzimin and other natural compounds need to be further optimized
to improve the potency and specificity and to gain more drug-like properties.
2.4.2. Block the Interaction between Substrate and the Proteasome
Rpn11 is not the only potential drug target in the 19S RP. The first reported inhibitor of the 19S
RP was ubistatin, which blocks the binding of ubiquitin chains to their receptors [151]. Ubistatins A
and B compete for the polyUb receptor Rpn10 and the shuttle protein Rad23 for their interactions
with polyUb chains (Table 3 and Figure 3) [151]. As a result, ubistatins inhibit protein degradation
in vitro [151]. More recently, a structural study revealed an interaction between ubistatin and ubiquitin.
Ubistatin directly interacts with a hydrophobic patch and the surrounding basic/polar residues on the
ubiquitin surface. Ubistatin shows a strong preference for K48 linkages over K11 and K63 linkages due
to differences in the conformation and distribution of the hydrophobic patches on the surfaces [152].
The major challenge to further develop ubistatins as therapeutics is their negative charge, which
precludes efficient membrane penetration, thereby limiting their potency in cells.
Another polyUb receptor in the 19S RP, Rpn13, is an attractive target for the development of
alternative proteasome inhibitors [39]. Rpn13 and the deubiquitinating enzyme that it activates, Uch37,
have been found to be important for cell cycle progression in cell culture [153], and increased expression
of the gene encoding Rpn13 (ADRM1) has been identified in several forms of cancer [154–157]. Multiple
efforts have been put forth to look for Rpn13 inhibitors. RA190, a bis-benzylidine piperidone, was the
first identified inhibitor of Rpn13. It was believed to covalently interact with Cys88 of Rpn13 and block
the binding of polyUb substrates (Table 3) [158]. RA190 induces the accumulation of polyUb proteins,
causes ER stress, and stabilizes proteasome substrates, including p53 [158]. It showed anti-tumor
effects in mouse models for MM and ovarian cancer [158]. A subsequent study suggests that RA190
has two synergistic mechanisms of action: targeting Rpn13 when it is not bound to the proteasome (at
Cys88), and inactivating Uch37 at the proteasome [159]. Recently, an improved compound with higher
potency, RA183, was developed and tested in mice [160]. Similar to RA190, RA183 is an irreversible
inhibitor targeting Cys88 of Rpn13 and inhibits tumor growth in a xenograft mouse model of ovarian
cancer (Table 3) [160]. In addition to RA190/RA183, a peptoid inhibitor, KDT-11, was identified as
a Rpn13 inhibitor that binds with a modest Kd of 1.7 µM (Table 3) [161]. KDT-11 causes ubiquitin
accumulation and acts synergistically with bortezomib in treating MM cells. KDT-11 is a reversible
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inhibitor that does not compete with RA190, indicating a different binding mechanism [161]. It should
be noted that “enones” like RA190 have been described as “pan-assay interference compounds,” or
PAINS, which raises concern about their specificity [162]. However, demonstrated examples of ways to
circumvent the specificity problem with thiol-reactive compounds are described below (Section 3.2.2).
Irrespective of the type of inhibitor, further support for inhibiting Rpn13 comes from the recent
development of a proteolysis-targeting chimeric molecule (PROTAC), WL40, that fuses RA190 with
thalidomide, targeting Rpn13 for degradation [163]. This molecule successfully inhibits MM cell
growth in a mouse xenograft model. In fact, the molecule shows improved MM cell death compared
to Rpn13 inhibitors. This presents a conundrum, though, because the PROTAC works by targeting
Rpn13 for proteasomal degradation, but the effect of the drug is to hamper proteasomal degradation.
Nonetheless, this proof-of-principle study shows that there could be some benefit to degrading a
proteasomal or proteasome-associated target rather than functionally hindering it. There is a lot of
excitement surrounding PROTACS like WL40 and their uses in selectively degrading proteins by
linking a ubiquitin ligase to a particular target; the advantages and disadvantages of this strategy are
reviewed elsewhere [164–166].
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Table 3. Inhibitors of non-20S UPS components.
Name Target IC50/Kd Mechanism
Capzimin Rpn11
0.3 µM (In vitro Rpn11 assay);
0.6 µM (UbG76V-GFP
degradation assay in cells)
Chelating the zinc ion in Rpn11, inactivating its DUB
activity [40]
Ubistatin B polyUb
10 µM
(CFTR ubiquitination assay in
cells)
Binding to the polyUb chain and blocking the
substrate/Ub receptor interaction [151,152]
RA190 Rpn13 Not Applicable
Covalently binding to cysteine residue 88 (Cys88) of
Rpn13 when it is not bound to the proteasome and
Uch37 at the proteasome [158–160]RA183
KDT-11 Rpn13 1.7 µM (Kd) Peptoid ligand binding to Rpn13 [161]
RIP-1 Rpt4
3.0 µM
(proteasome-mediated stripping
of the Gal4-VP16 protein from
DNA in vitro)
Inhibiting the protein unfolding activity of the 19S
RP [167,168]
2.4.3. Block Substrate Translocation into the 20S CP: Proteasome ATPase inhibitors
The third potential target in the 19S RP is the proteasomal ATPase, which provides the energy
to power substrate translocation into the 20S CP and therefore facilitates protein degradation. RIP-1
was the first identified peptoid inhibitor targeting Rpt4 (PSMC6), a subunit of the proteasome
ATPase [167,168]. RIP-1 biochemically blocks the protein unfolding activity of the 19S RP and inhibits
turnover of the proteasome substrate p27 in cells (Table 3 and Figure 3) [167]. However, since the
discovery of RIP-1 in 2007, there have been no follow-up studies to further understand the biological
effects of this inhibitor. It will be interesting to understand its selectivity towards the proteasomal
ATPase, given the abundance and similarity of ATPases in cells.
3. Perspective on the Use of Proteasome Inhibitors in Clinic
The initial development and clinical success of 20S proteasome inhibitors validated the maintenance
of proteostasis as a therapeutic approach for treating human diseases. Proteasome inhibitors have
revolutionized the treatment of MM, greatly extending patients’ lives. However, part of the success
of proteasome inhibitors thus far is attributed to unique characteristics of transformed plasma cells.
Additionally, the development of resistance and the toxicity profiles of currently used inhibitors cast
doubts over the future utility of proteasome inhibition. The essential role of the proteasome in cell
biology makes it difficult to envisage proteasome inhibition as a single therapeutic strategy for treating
a range of human illnesses. To use proteasome inhibition to its full potential, it is critical to develop
deeper understandings of the biological pathways affected by proteasome inhibition and strategies to
confer inhibitor specificity to cell and proteasome types. This includes targeting other components of
the UPS than the 20S proteasome itself. It also includes understanding mechanisms of proteasome
resistance and trying to develop ways to stop resistance from developing.
3.1. Combatting Proteasome Inhibitor Resistance
Cancer cells are often described as resilient cells that continue growing despite efforts to stop them.
True to the description, there have been multiple observed mechanisms of resistance to proteasome
inhibitors in the lab and the clinic. Combatting these resistance mechanisms can serve as a potentially
useful strategy for making proteasome inhibitors more effective for treating blood-based cancers and
for expanding their profiles to treat solid tumors. Combination therapies comprised of a proteasome
inhibitor and an inhibitor targeting a resistance mechanism is one example of a strategy that can be
employed, much like amoxicillin and clavulanate are often used together to treat bacterial infections.
Mechanisms of resistance to proteasome inhibitors (especially bortezomib) seen in the lab or clinic
include, but are not limited to mutations in PSMB5 (see Section 2.2.1), aberrant expression of UPS
Molecules 2020, 25, 671 14 of 30
pathway components [169–171], induction of drug eﬄux from cells, and activation of signaling
cascades that promote cell survival [172]. An early rationale for administering combination therapies
to treat cancer was that drugs with nonoverlapping mechanisms would reduce the chances of
developing therapeutic resistance [173]. The combination-therapy strategy showed promise for treating
BRAFV600E colorectal cancers [174]. BRAFV600E melanomas, which have low expression of EGFR, are
treatable with RAF inhibitors (e.g., vemurafenib); however, BRAFV600E colorectal cancers adapt to RAF
inhibitors through compensatory activation of the EGFR and MAPK signaling pathways [175,176]. An
understanding of this biology paved the way for the encouraging results of a clinical trial for combination
BRAF–EGFR–MEK inhibitor therapy for treating BRAFV600E colorectal-cancer patients [174]. Although
more has to be done to optimize the treatment regimen, this example highlights the power of
understanding compensatory-resistance mechanisms for improving cancer therapies.
An interesting mechanism of resistance to sublethal proteasome inhibition involves activation of ER
resident transcription factor Nrf1/NFE2L1. Nrf1 is constitutively retrotranslocated from the ER lumen
to the cytoplasm, where it is degraded by the proteasome under homeostatic conditions [177–179].
However, if proteasome activity is inhibited or hindered, then Nrf1 is instead cleaved by the DDI2
protease in the cytoplasm to form the active transcription factor that translocates to the nucleus and
enhances transcription of UPS genes, among others [180,181]. This allows for a “bounce-back” response
in which cells react to proteasome inhibition by producing more proteasome subunits. As an aspartyl
protease with a substrate binding site, DDI2 might be a promising, potentially “druggable” candidate
for combination therapies with proteasome inhibitors. However, for this to be a viable strategy,
demonstration is critical of the requirement of DDI2 and Nrf1 for this compensatory mechanism in
actual human-cancer-patient samples. Additionally, more thorough characterization of the DDI2
cleavage mechanism, including reconstitution of the activity of the human protein and characterization
of its other roles in the cell, are critical. In addition to DDI2, Nrf1 deglycosylation by the NGLY1
enzyme was demonstrated to be important for Nrf1 activity [182,183]. Although loss of NGLY1 is
responsible for a rare human genetic disorder, and the range of its substrates necessitate thorough
characterization [184], inhibiting NGLY1 might serve as another druggable target in this pathway.
An additional metabolic mechanism of resistance was recently described and can potentially be
exploited therapeutically. The mechanism involves a surprising relationship between proteasome
inhibition and mitochondrial metabolism [185]. Resistance to proteasome inhibitors is related to a shift
from glycolysis to oxidative phosphorylation, and such a shift renders cells especially sensitive to the
small molecule elesclomol, whose target is the mitochondrial reductase FDX1. This finding raises the
possibility that perhaps there are other resistance pathways that have not yet been discovered that can
be exploited for therapeutic intervention.
Cumulatively, understanding mechanisms of resistance to proteasome inhibitors, and how to
target them using combination therapies can help improve the efficacy of treatments for MM and MCL,
and can potentially broaden the scope of proteasome inhibitors to the treatment of solid tumors—a
holy grail. By increasing the extent and duration of proteasome inhibition by concomitantly inhibiting
a resistance mechanism, cancer cells on the brink of apoptosis might be pushed over the edge [89].
3.2. Other UPS Inhibitors
3.2.1. VCP/p97 Inhibition
There are many UPS components other than the 20S CP that can serve as viable targets for
therapeutic intervention. One very promising oncological target is vasolisin-containing protein
(VCP)/p97, an essential and conserved homohexameric AAA+ ATPase that has been demonstrated
in recent years to be involved in numerous cellular pathways [186]. p97 is central to proteostasis by
serving as a “segragase” that extracts challenging UPS substrates from cellular structures (downstream
of E3 ubiquitin ligases) [187,188]. For example, p97 is essential for extracting ER-associated substrates
during ERAD and tRNA-nascent chains from ribosomes that stall during translation [189]; p97 also
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separates protein aggregates so that the proteasome can degrade them. There are also nondegradative
roles for p97, such as in endosomal trafficking and chromatin remodeling [190]. There have been
substantial efforts to understand the structure and mechanism of p97, and the nature of its interaction
with various adapter proteins that are required for its function in different pathways [191–194]. Because
p97 is essential, it cannot be completely eliminated from cells without inducing the UPR and apoptosis.
However, cancer cells appear to have a heightened dependence on p97 than noncancerous cells do,
and hence more rapid apoptosis upon p97 depletion [89].
There have been substantial efforts to find effective and potent p97 inhibitors, and despite many
tool compounds that can be used in the lab, there has been only one that made it to phase 1 clinical
trials: CB-5083 developed by Cleave Biosciences. CB-5083 is an orally available, potent inhibitor that
shows efficacy in tumor models that are insensitive to proteasome inhibitors. Additionally, CB-5083
inhibition is more efficacious in solid tumor models than proteasome inhibitors. Transcriptomics
studies with MM cell lines indicate that the cellular response to CB-5083 is distinct from that of
proteasome inhibitors, supporting the notion that targeting different components of the UPS can be
beneficial for treating different diseases or disease states [195]. Interestingly, the transcription factor
Nrf1 is an ERAD substrate and depends on p97 for its retrotranslocation [179]. CB-5083 inhibits
Nrf1-mediated proteasome gene upregulation, thereby inhibiting a potentially important form of
resistance to proteasome inhibition. While the pre-clinical data were promising for this first-in-class
compound, clinical trials for its efficacy in treating MM were terminated in 2018.
P97 inhibition can be effective in treating diseases other than cancer. Inclusion body myopathy
with early-onset Paget disease and frontotemporal dementia (IBMPFD) is caused by mutations in
VCP [196,197]. Studies from a biochemical reconstitution of p97 demonstrate that IBMPFD mutants
show enhanced p97 unfoldase activity [198,199]. Therefore, it is possible that inhibiting p97 activity
can be efficacious for treating IBMPFD.
3.2.2. Inhibiting other UPS Components
Despite the diversity and the number of E3 ubiquitin ligases, which confer substrate specificity
to the ubiquitination reaction, there are only two mammalian E1 ubiquitin-activating enzymes.
Theoretically, inhibiting the E1 reaction would inhibit all ubiquitin-dependent pathways in cells, both
degradative and non-degradative. The first E1 inhibitor, PYR-41, was shown to attenuate NF-kB
activation and proteasomal degradation of IkB. Proof-of-principle studies also demonstrated that it
can differentially kill cancer cells [200]. A more potent and selective inhibitor, TAK-243, was recently
reported to cause complete loss of cellular ubiquitylation, impaired cell cycle progression, and impaired
DNA damage repair [201]. TAK-243 shows efficacy in tumor models and is under investigation as a
clinical candidate for treating myelodysplastic syndrome and leukemia.
Targeting E3 ubiquitin ligases could be efficacious for finding more specific and less toxic inhibitors
of the UPS. There are over 600 E3 ligases in mammalian cells that catalyze a range of ubiquitin linkages
and chain types. Ubiquitinated proteins can have both degradative and nondegradative fates. The three
main families of ligases, RING, U-box, and HECT-containing E3s, have different characteristics and
properties. Most efforts to find E3 inhibitors have focused on MDM2, IAP, and SCF [202]. The IAP
(antiapoptotic proteins) family inhibits proapoptotic caspases and Smac proteins. One target of IAP is
RIP1, which activates NF-kB. Therefore, inhibiting RIP1 ubiquitylation inhibits NF-kB activation, and
this has been exploited as a potential therapeutic strategy [203–205].
An indirect approach for inhibiting cullin-RING ubiquitin ligases, the largest class of E3 ligases,
is to inhibit their activation by neddylation, post-translational modification similar to ubiquitylation.
Pevonedistat (MLN4924/TAK-924) is a potent inhibitor of the Nedd8-activating enzyme (similar to the
ubiquitin-activating E1 enzyme) that has shown efficacy in killing a variety of cancer-cell types, and
has been under clinical investigation for treating leukemia in addition to solid tumors [206–208].
As described above, inhibiting Rpn11, the de-ubiquitinating (DUB) enzyme in the lid of the 19S RP,
has proven efficacious in the lab. DUBs in general are promising targets for cancer therapies because
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they are aberrantly activated or expressed in certain cancer types. A challenge with identifying potent
and selective DUB inhibitors is that DUBs contain an active-site cysteine, and many DUB inhibitors
that have been discovered and investigated are thiol-reactive molecules. Therefore, they have the
potential problem of reacting nonspecifically with exposed cysteine residues in various proteins. One
way to circumvent this problem and to confer specificity is to have multiple binding modes or binding
sites distal to the catalytic cysteine. This has been exploited for finding inhibitors of the DUB Usp7, for
example, which show efficacy in tumor models [209–212]. There is precedent for bringing thiol-reactive
drugs to the clinic [213–217]. The recent development of AMG 510 by Amgen for treating solid tumors
with a particular KRAS-G12C mutation further demonstrates that cysteine-reactive drugs can advance
to clinical trials [218].
Besides Rpn11, there are two proteasomal non-JAMM-domain-containing DUBs, Usp14 and
Uch37 [8,219]. Interestingly, the activities of these DUBs appear to reduce degradation of their
substrates, presumably because they are not coupled to the ATPase activity of the 19S RP. Consistent
with this activity, a well-characterized small-molecular inhibitor of Usp14, IU1, showed increased
degradation of model substrates, biochemically and in cells [219,220]. Recent structural evidence
demonstrated that IU1 is specific for Usp14 by binding to an allosteric site that blocks access of
ubiquitin to the active site [221]. This class of inhibitor could be useful for treating diseases in which
proteasome activity needs to be activated, such as neurodegenerative diseases. Interestingly, b-AP15,
a dual inhibitor of Usp14 and Uch37, was shown to prevent protein degradation and inhibit tumor
progression in acute myeloid leukemia models [222].
3.3. Other Indications for Proteasome Inhibitors
Although clinical proteasome inhibitors were originally developed to treat cancers, the rich
biology of the proteasome and its essentiality in many processes make it a promising target for other
indications, too. For example, there is a straightforward connection between proteasome inhibition
and immune disorders. The proteasome is involved in generating antigens for presentation by MHC
Class I, and proteasome inhibitors are effective at targeting antibody-producing B cells. As such,
bortezomib and carfilzomib continue to be explored as therapies for antibody-mediated allograft
rejection (AMR) [223–225]. Proteasome inhibitors might be useful for treating AMR because they
reduce the number of human leukocyte antigen (HLA) antibodies [226]. Bortezomib showed early
efficacy when used alone according to the MM treatment regimen to treat rejection following renal
transplantation [227]. Bortezomib has also been used in combination with other AMR treatments [228].
Additionally, proteasome inhibitors have been efficacious in treating heart, pancreas, and lung allograft
rejection [229–231]. There are also clinical trials that were completed or are underway to evaluate
the use of proteasome inhibitors to treat graft-versus-host disease and other transplantation-related
immune disorders (clinicaltrials.gov).
Another interesting clinical application of proteasome inhibition is in the treatment of malaria [232–235].
Malaria parasites contain their own form of the 26S proteasome in the cytoplasm and nucleus. Additionally,
in silico predictions and biochemical analyses suggest that a significant portion of the Plasmodium falciparum
proteome can be ubiquitinated during asexual reproduction, and ubiquitination is associated with resistance
to antimalarial agents [236]. Selective inhibitors of the protozoal proteasome have proven effective in
killing P. falciparum while sparing human cells [237,238]. Because the proteasome is vital in all stages of
the P. falciparum life cycle in human hosts, it remains a promising antimalarial drug target that merits
further investigation.
While the protozoan proteasome is an unusual drug target, even more surprising is the use
of proteasome inhibitors as antibiotics. Although the proteasome is essential in eukaryotes, there
are conditionally essential proteasomal genes in many bacterial Actinomycetales and Nitrospirales
lineages [239]. This includes highly pathogenic species Mycobacterium tuberculosis, a major global
threat affecting at least 10 million people in 2017 [240–244]. Researchers have turned to the M.
tuberculosis proteasome as a potential drug target because of its importance for resistance to oxidative
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and nitrosative stresses in a human host. As with malarial proteasome inhibitors, molecules targeting
the M. tuberculosis proteasome must be selective over human proteasomes. Significant efforts were
made to identify selective M. tuberculosis proteasome inhibitors [245,246], and with growing interest
in using proteasome inhibitors to treat infectious diseases amid the threat of drug resistance, this is
an exciting time to investigate fundamental properties of bacterial proteasomes and novel ways to
distinguish them from human proteasome complexes [246].
4. Conclusions
Proteasome inhibitors have proven efficacious in the clinic for treating hematological malignancies.
Their efficacy for treating these cancer types and for expanding their indications to solid tumors has
been challenged by the development of resistance and toxicity, in addition to past limitations in crossing
the blood-brain barrier and therefore treating glioblastomas. However, innovative applications of
proteasome inhibitors that can have clinical relevance continue to be uncovered. Considering the
importance of the proteasome for antigen presentation by immune cells, uses for proteasome inhibitors
(especially at low doses) in modulating antigen presentation and immunoproteasome-specific inhibitors
will clearly be active areas of basic and applied research in the coming years. Exploring specific
degradation trajectories of target proteins can also prove to be a viable approach for finding specific
inhibitors, as there is tremendous diversity in the players involved in the UPS. Finding the right
balance between inhibiting the proteasome “just enough” and maintaining proteasome activity where
it is needed will continue to be a challenge that will need to be addressed. However, fundamental
and applied research pertaining to the proteasome and proteasome inhibitors, and ongoing and new
clinical trials that make use of proteasome inhibitors for treating a growing number of diseases, will
inform future drug discovery efforts. The proteotoxic crisis exists in many cell types and is central to a
vast number of human diseases, and as long as this is the case, there will be a need for more specific
and selective proteasome inhibitors (Figure 4).Molecules 2019, 24, x FOR PEER REVIEW 18 of 30 
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